Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
GREENWAY MEDICAL TECHNOLOGIES INC (GWAY)
|
|
| Income Statement |
Product |
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-13 | Jun-30-12 | Jun-30-11 | Jun-30-10 | Mar-31-10 | Jun-30-09 |
| | 10-K | 10-K | 10-K | 10-K | S-1 | S-1/A |
| Revenues: |
| Support services | 44.6 | 33.1 | 22.4 | 16.0 | | |
| Training and consulting services | 19.4 | 27.8 | 18.4 | 11.9 | | |
| Other | 134.8 | 124.0 | 89.8 | 64.6 | | |
| Total revenues [+] | 198.8 | 185.0 | 130.6 | 92.5 | 38.8 | 48.7 |
| Services | 134.8 | 124.0 | 89.8 | 64.6 | | |
| Technology services | 19.4 | 27.8 | 18.4 | 11.9 | | |
| Revenue growth [+] | 7.5% | 41.6% | 41.1% | 90.0% | | |
| Support services | 34.4% | 48.0% | 39.7% | | | |
| Training and consulting services | -30.2% | 51.4% | 54.9% | | | |
| Cost of goods sold [+] | 64.5 | 55.9 | 40.4 | 27.8 | 17.8 | 21.4 |
| Cost of technology services | 13.7 | 18.9 | 13.6 | 8.2 | | |
| Gross profit | 134.4 | 129.1 | 90.2 | 64.7 | 21.0 | 27.3 |
| Gross margin | 67.6% | 69.8% | 69.1% | 70.0% | 54.2% | 56.0% |
| Selling, general and administrative | 58.3 | 47.6 | 37.4 | 27.7 | 16.9 | 20.4 |
| Research and development | 19.0 | 15.7 | 8.2 | 6.0 | 5.4 | 5.8 |
| Other operating expenses | 64.0 | 61.0 | 40.8 | 27.9 | | |
| EBITDA [+] | 2.2 | 9.2 | 5.1 | 3.6 | | 1.5 |
| EBITDA growth | -75.9% | 82.2% | 42.2% | 131.2% | | |
| EBITDA margin | 1.1% | 5.0% | 3.9% | 3.8% | -3.0% | 3.2% |
| Depreciation | 8.9 | 4.3 | 1.3 | 0.3 | | 0.4 |
| EBITA | -6.7 | 4.9 | 3.8 | 3.2 | -1.2 | 1.1 |
| EBITA margin | -3.4% | 2.7% | 2.9% | 3.5% | -3.0% | 2.3% |
| Amortization of intangibles | 0.2 | 0.1 | | 0.1 | | |
| EBIT [+] | -6.9 | 4.9 | 3.8 | 3.1 | -1.2 | 1.1 |
| EBIT growth | -242.4% | 27.3% | 21.8% | 175.9% | | |
| EBIT margin | -3.5% | 2.6% | 2.9% | 3.4% | -3.0% | 2.3% |
| Interest income, net [+] | 0.3 | 0.1 | 0.0 | -0.1 | 0.3 | -0.1 |
| Interest expense | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 |
| Interest income | 0.4 | 0.1 | 0.1 | 0.0 | 0.3 | 0.1 |
| Other income (expense), net | -0.1 | 0.0 | -0.1 | 0.0 | 0.0 | -0.1 |
| Pre-tax income | -6.7 | 4.9 | 3.8 | 3.0 | -0.9 | 1.0 |
| Income taxes | -1.6 | 2.0 | -29.2 | 0.1 | 0.0 | 0.0 |
| Tax rate | 23.9% | 40.2% | | 4.9% | 0.0% | 2.6% |
| Net income | -5.1 | 31.3 | -22.0 | -5.2 | 0.0 | 0.0 |
| Net margin | -2.5% | 16.9% | -16.8% | -5.6% | 0.0% | 0.0% |
| |
| Basic EPS [+] | ($0.17) | $1.66 | ($1.90) | ($0.48) | ($0.74) | ($0.81) |
| Growth | -110.3% | -187.6% | 292.3% | -40.2% | | |
| Diluted EPS [+] | ($0.17) | $1.23 | ($1.90) | ($0.48) | ($0.74) | ($0.81) |
| Growth | -113.9% | -165.0% | 292.3% | -40.2% | | |
| |
| Shares outstanding (basic) [+] | 29.6 | 18.8 | 11.6 | 10.7 | 0.0 | 0.0 |
| Growth | 57.3% | 62.4% | 8.4% | 107283.0% | | |
| Shares outstanding (diluted) [+] | 29.6 | 25.4 | 11.6 | 10.7 | 0.0 | 0.0 |
| Growth | 16.6% | 119.1% | 8.4% | 107283.0% | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|